Infrastructure needs for translational integration of mouse and human trials

Cold Spring Harbor Protocols

Volumn 2013, Issue 12, 2013, Pages 1109-1114

  Clohessy, John G ^a   de Stanchina, Elisa ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL HOUSING; ANIMAL HUSBANDRY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; IMAGING; MOUSE MODEL; NEOPLASM; PHARMACY; REPRODUCIBILITY; SAMPLE SIZE; STUDY DESIGN; VETERINARIAN; BIOLUMINESCENCE; BODY WEIGHT; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DNA INTEGRATION; EXPERIMENTAL DESIGN; GOOD LABORATORY PRACTICE; HUMIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; ROOM TEMPERATURE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; TREATMENT OUTCOME;

EID: 84889073619     PISSN: 19403402     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.top078782     Document Type: Article

References (10)

1. 21CFR58-Code of Federal Regulations Title 21-Food and Drugs. Chapter I: Food and Drug Administration. Department of Health and Human Services. Subchapter A: General. Part 58 Good Laboratory Practices for Nonclinical Laboratory Studies. U.S. Food and Drug Administration.
2. Revised as of April 1, 2012. http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfCFR/CFRSearch.cfm?CFRPart=58&showFR=1.
3. Abate-Shen C., Pandolfi PP. 2013. Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials. Cold Spring Harb Protoc doi: 10.1101/pdb.top078774.
4. Chen Z., Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J., Li J, et al. 2012. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483: 613-617. doi: 10.1038/nature10937.
5. Chesi M., Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK., Johnstone RW, Bergsagel PL. 2012. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120: 376-385.
6. Innominato PF., Lévi FA, Bjarnason GA. 2010. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev 62: 979-1001.
7. Lunardi A., Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R., Bianconi M, Stack EC, et al. 2013. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 45: 747-755.
8. Nardella C., Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. 2011. The APL paradigm and the "co-clinical trial" project. Cancer Discov 1: 108-116.
9. Regales L., Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, et al. 2009. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119: 3000-3010.
10. 2inhalation affects potassium levels in mice. J Am Assoc Lab Anim Sci 49: 316-322.